Skip to main content

Market Overview

Recap: Clearside Biomedical Q1 Earnings


Shares of Clearside Biomedical (NASDAQ:CLSD) rose after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 85.71% over the past year to ($0.13), which missed the estimate of ($0.10).

Revenue of $34,000 decreased by 99.17% from the same period last year, which missed the estimate of $2,120,000.


Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 17, 2021

Time: 04:30 PM

ET Webcast URL:

Price Action

52-week high: $4.53

52-week low: $1.25

Price action over last quarter: down 25.47%

Company Description

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision.


Related Articles (CLSD)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings